title: Genomic DNA from LC15 at T1

description:
Sample 22
LC15-1
Case at T1 LC sample.

value: male


title: Genomic DNA from LC13 at T2

status: Public on Sep 24 2014

type: genomic

city: Iowa City

first: Robert

middle: Alan

last: Philibert

state: IA

address: 500 Newton Rd

country: USA

institute: University of Iowa

description:
Sample 20
LC13-2
Case at T2 LC sample.

hyb_protocol: Bisulfite-converted DNA was amplified, fragmented and hybridized to Illumina Infinium Human Methylation450 BeadChip using the standard Illumina protocol.

scan_protocol: Arrays were imaged using BeadArray Reader using standard recommended Illumina scanner setting.

data_processing: Genome Studios V2011.1.

label: Cy5 and Cy3

molecule: genomic DNA

organism: Homo sapiens

source_name: Case at T2

label_protocol: Standard Illumina protocol.

extract_protocol: Genomic DNA was extracted and purified from LC samples using the QIAmp DNA Blood Mini Kit according to standard instructions.

tag: cell type

value: lymphocyte cells (LC)

tag: gender

value: female

tag: disease state

value: alcohol consumption

tag: sample type

value: case

tag: time point

tag: individual


title: iPS-MSC_M2C6_d7

type: RNA

city: Aachen

first: Wolfgang

last: Wagner

address: Pauwelsstrasse 20

department: Helmholtz Institute for Biomedical Engineering

country: Germany

institute: RWTH Aachen University

hyb_protocol: Affymetrix protocol

scan_protocol: Arrays were scanned using Affymetrix GeneChip Scanner 3000.

data_processing: CEL files were processed using the Affymetrix Power Tools (APT) Software Package. Normalization was done employing RMA (Irizarry et al., Biostatistics 4, 249-264, 2003).

label: biotin

molecule: total RNA

source_name: iPSC-derived MSCs (iPS-MSCs)

label_protocol: Affymetrix protocol

extract_protocol: Total RNA was isolated with the NucleoSpin® miRNA Isolation Kit (Macherey-Nagel, Düren, Germany).

treatment_protocol: MSCs were isolated from bone marrow (tibia plateau) after written consent using guidelines approved by the Ethic Committee of the Use of Human Subjects at the University of Aachen (permit number: EK128/09). MSCs from three donors were infected with pMXs based retroviruses (Addgene, Cambridge, MA, USA) carrying the OCT3/4, SOX2, KLF4, and c-MYC genes. Established iPSCs were maintained on MEFs in DMEM/F12 medium supplemented with Glutamax, 20% knockout serum replacer, 1% nonessential amino acids, 1x penicillin/streptomycin, 1x L-glutamine, 0.1 mM β-Mercaptoethanol, and 50 ng/ml basic fibroblast growth factor (Peprotech, Hamburg, Germany). To exclude contamination of feeder layer cells, iPSCs were adjusted to a feeder-free system on matrigel (BD Biosciences, San Jose, CA, USA) in mTeSR™1 medium (Stemcell Technologies, Vancouver, BC, Canada) for at least three passages. Cells were passaged every 5-6 days enzymatically with dispase (1 g/ml, Stemcell Technologies). For re-differentiation of iPSC towards iPS-MSCs medium was simply exchanged for MSC standard medium supplemented with 10% human platelet lysate (hPL) for 7 days, and cells were then further passaged in culture wells coated with 0.1% gelatin (Sigma-Aldrich, St. Louis, CA, USA).

tag: donor

value: donor 2; clone 6

value: iPS-MSC

tag: passage

value: passage 0


title: iPS-MSC_M2C6_d21

value: passage 2


title: iPS-MSC_M2C6_d14

value: passage 1


title: Genomic DNA from LC8

description:
Sample 12
LC8
Control LC sample.

source_name: Control

value: control


title: iPSC_M2C6

source_name: Bone marrow MSC-derived iPS cells (iPSCs)

value: iPSC

value: passage 34


title: Genomic DNA from LC6

description:
Sample 9
LC6
Control LC sample.


title: Genomic DNA from LC7 at T2

description:
Sample 11
LC7-2
Case at T2 LC sample.


title: Genomic DNA from LC5 at T2

description:
Sample 8
LC5-2
Case at T2 LC sample.


title: Control 11

city: Toronto

first: Dafna

middle: D

last: Gladman

state: Ontario

address: 60 Leonard Ave

department: Rheumatology Research

country: Canada

institute: Toronto Western Research Institute

description: Biological replicate 11 of 12.

hyb_protocol: Total RNA was labelled and hybridized following Agilent's Two-Color Microarray-Based Gene Expression Analysis Protocol V5.7, using the Low RNA Input Linear Amplification Kit, 2-colour, QuickAmp Lot #006043422, Hybridization Kit Lot #0006044567.

scan_protocol: Arrays were scanned on an Agilent G2565C DNA Scanner. Images were quantified using Agilent Feature Extraction Software (version 10.5) extraction protocol GE2_105_Dec08.

data_processing: R/Bioconductor package limma was used for background correction, quantile and loess normalization.

source_name: Whole blood

extract_protocol: RNA was extracted using the PAXgene Blood RNA Kit following the manufacturer's instructions (PreAnalytiX, Feldbachstrasse, Switzerland). RNA quality was assessed by Agilent 2100 Bioanalyzer and all samples had RIN>7.

treatment_protocol: Whole blood was collected PAXgene tubes (PreAnalytiX, Feldbachstrasse, Switzerland), incubated at room temperature for 2 hours and stored frozen at -80 degrees celcius until extraction

tag: tissue

value: whole blood

tag: condition

value: Unaffected control

value: Female

tag: batch

tag: psoriasis duration

tag: age of psoriasis onset

source_name: Human Universal Reference RNA (Stratagene)

tag: source

value: 10 human cell lines:Adenocarcinoma, mammary gland; Hepatoblastoma, liver; Adenocarcinoma, cervix; Embryonal carcinoma, testis; Glioblastoma, brain; Melanoma; Liposarcoma; Histiocytic lymphoma, macrophage, histocyte; Lymphoblastic leukemia, T lymphoblast; Plasmacytoma, myeloma, B lymphocyte


title: Control 10

description: Biological replicate 10 of 12.

label_protocol: Total RNA was labelled and hybridized following Agilent's Two-Color Microarray-Based Gene Expression Analysis Protocol V5.7, using the Low RNA Input Linear Amplification Kit, 2-colour, QuickAmp Lot #006043422, Hybridization Kit Lot #0006044567.

value: Male


title: Genomic DNA from LC9 at T1

description:
Sample 13
LC9-1
Case at T1 LC sample.

source_name: Case at T1

value: lymphocyte cells (LC)

value: male


title: Genomic DNA from LC7 at T1

description:
Sample 10
LC7-1
Case at T1 LC sample.

value: female

value: alcohol consumption


title: Control 12

description: Biological replicate 12 of 12.


title: Control 8

description: Biological replicate 8 of 12.


title: Control 6

description: Biological replicate 6 of 12.


title: Control 5

description: Biological replicate 5 of 12.


title: Control 9

description: Biological replicate 9 of 12.


title: Control 7

description: Biological replicate 7 of 12.


title: Genomic DNA from LC12

description:
Sample 18
LC12
Control LC sample.


title: Genomic DNA from LC1 at T2

description:
Sample 2
LC1-2
Case at T2 LC sample.

value: case


title: Genomic DNA from LC5 at T1

description:
Sample 7
LC5-1
Case at T1 LC sample.


title: Genomic DNA from LC4

description:
Sample 6
LC4
Control LC sample.


title: Genomic DNA from LC3 at T2

description:
Sample 5
LC3-2
Case at T2 LC sample.


title: Control 4

description: Biological replicate 4 of 12.


title: iPS-MSC_M5C1_d21 [Methylation]

hyb_protocol: Bisulfite converted DNA was amplified, fragmented and hybridized to Illumina Infinium HumanMethylation450 Beadchip using standard Infinium HD Methylation Assay protocol.

scan_protocol: Standard Infinium HD Methylation Assay protocol

data_processing: Initial analysis was performed by the GenomeStudio 2010.3 (Modul M Version 1.8.5). Data were normalized with internal controls according to Illumina´s standard procedures. Methylation level at each locus was calculated with the GenomeStudio Methylation module as beta-value (ranging from 0 to 1). The number of beads per feature varies between chips and beta-values were calculated as average of at least three technical replica.

extract_protocol: Genomic DNA was isolated using the Qiagen DNA Blood Midi Kit.

value: donor 5; clone 1

value: iPS-MSC


title: Control 3

description: Biological replicate 3 of 12.


title: Genomic DNA from LC2

description:
Sample 3
LC2
Control LC sample.


title: Genomic DNA from LC10

description:
Sample 15
LC10
Control LC sample.


title: Control 2

description: Biological replicate 2 of 12.


title: Genomic DNA from LC3 at T1

description:
Sample 4
LC3-1
Case at T1 LC sample.


title: Cutaneous psoriasis without arthritis PsC 20

description: Biological replicate 20 of 20.

value: Cutaneous psoriasis without arthritis


title: Cutaneous psoriasis without arthritis PsC 18

description: Biological replicate 18 of 20.


title: Genomic DNA from LC1 at T1

description:
Sample 1
LC1-1
Case at T1 LC sample.


title: Cutaneous psoriasis without arthritis PsC 19

description: Biological replicate 19 of 20.


title: Control 1

description: Biological replicate 1 of 12.


title: Cutaneous psoriasis without arthritis PsC 15

description: Biological replicate 15 of 20.


title: Cutaneous psoriasis without arthritis PsC 16

description: Biological replicate 16 of 20.


title: Cutaneous psoriasis without arthritis PsC 17

description: Biological replicate 17 of 20.


title: iPS-MSC_M5C1_d35 [Methylation]

label_protocol: Standard Infinium HD Methylation Assay protocol

value: passage 4


title: iPS-MSC_M4C4_d21 [Methylation]

value: donor 4; clone 4

value: passage 2


title: iPS-MSC_M2C6_d28 [Methylation]

value: donor 2; clone 6

value: passage 3


title: Genomic DNA from LC9 at T2

description:
Sample 14
LC9-2
Case at T2 LC sample.


title: iPS-MSC_M2C6_d21 [Methylation]


title: iPS-MSC_M2C6_d35 [Methylation]


title: RCC sample pre vaccination #8

city: Münster

first: Michael

last: Grau

state: Nordrhein-Westfalen

address: Albert-Schweitzer-Campus 1

department: Faculty of Medicine

institute: University of Münster

description: primary RCC sample, before vaccination

hyb_protocol: RNA hybridisation was conducted by AROS Applied Biotechnology AS (Aarhus, Denmark) using the Affymetrix GeneTitan System and standard hybridization conditions for the HuGene 1.1 ST array plate (Affymetrix, Inc., Santa Clara, USA)

scan_protocol: Data Scanning was performed by AROS Applied Biotechnology AS (Aarhus, Denmark) using the Affymetrix GeneTitan System and Command Console ® Software (AGCC) version 4.0 (Affymetrix, Inc., Santa Clara, USA)

data_processing: Raw CEL data were RMA background corrected and then quantile-normalized. Probes were aggregated to Entrez Gene probesets as defined by the custom CDF [1] as described in [2] via median polish.  [1]http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/14.1.0/entrezg.download/HuGene11stv1_Hs_ENTREZG_14.1.0.zip  [2]M. Dai, F. Meng et al. (2005) Evolving Gene/Transcript Definitions Significantly Alter the Interpretation of GeneChip Data. Nucleic Acid Research 33 (20), e175.

source_name: PMBCs

label_protocol: RNA labelling was conducted by AROS Applied Biotechnology AS (Aarhus, Denmark) using the Nugen Pico WTA System and Nugen Encore Biotin Module (NuGen, San Carlos, USA)

growth_protocol: Whole blood samples were taken from healthy controls and RCC patients before and at week 6 and 14 of vaccination. PBMCs were prepared from heparinized whole blood by density gradient centrifugation on Lymphoprep (Progen, Heidelberg, Germany). Cells were harvested and washed four times with PBS at low speed to remove platelets. PBMCs were then stored in the vapour phase of liquid nitrogen until total RNA extraction.

extract_protocol: Total RNA was isolated using the NucleoSpin RNAII Kit (Macherey Nagel, Germany) according to the manufacturer’s protocol.

treatment_protocol: RCC patients were immunized with a gene-modified allogeneic tumor cell vaccine over 22 weeks. PBMCs of RCC patients were harvested for GEP before and at week 6 or 14 after the first vaccination.

tag: measurement group

tag: treatment group

value: before vaccination


title: RCC sample pre vaccination #9

description: primary RCC sample, before vaccination


title: iPSC_M5C1 [Methylation]

value: iPSC

value: passage 34


title: iPSC_M4C4 [Methylation]

value: passage 32


title: RCC sample pre vaccination #7

description: primary RCC sample, before vaccination


title: Cutaneous psoriasis without arthritis PsC 14

description: Biological replicate 14 of 20.

value: whole blood

value: Female

value: 10 human cell lines:Adenocarcinoma, mammary gland; Hepatoblastoma, liver; Adenocarcinoma, cervix; Embryonal carcinoma, testis; Glioblastoma, brain; Melanoma; Liposarcoma; Histiocytic lymphoma, macrophage, histocyte; Lymphoblastic leukemia, T lymphoblast; Plasmacytoma, myeloma, B lymphocyte


title: Cutaneous psoriasis without arthritis PsC 13

description: Biological replicate 13 of 20.


title: Namalwa DNA methylation

city: Freiburg

first: Pierre

middle: Daniel

last: Cauchy

state: Baden-Württemberg

address: Breisacher Str. 115

department: Zentrum für Translationale Zellforschung

institute: University Medical Center Freiburg

hyb_protocol: HumanMethylation 450K BeadChip

scan_protocol: HumanMethylation 450K BeadChip

data_processing: For the analysis of methylation sample data, image scanning, processing, feature extraction and normalization were performed in Illumina GenomeStudio. All intensities are combined in the TPS1928_SampleMethylationProfile_FinalReport_20Jun11_HL_NHL.txt file. Higher-level analysis was performed in R using IMA (https://www.rforge.net/IMA/index.html) followed by a custom R pipeline where probe  methylation levels were aggregated per promoter. Promoter methylation fold changes were computed as log2 ratios

label: Biotin, DNP

source_name: Burkitt's lymphoma cell line

label_protocol: HumanMethylation 450K BeadChip

growth_protocol: Cells lines from Hodgkin's lymphoma (L1236 and L428), Pro-B lymphoblastic leukemia (Reh) and Burkitt's lymphoma (Namalwa) were grown in IMDM medium containint 10% FCS, penicillin 100 U/mL, and streptomycin 50 pg/mL and incubated at 37C in a humidified atmosphere containing 5% CO2, with cell densities kept under 5x105 per ml

extract_protocol: Phenol-choroform

tag: cell line

value: Namalwa

value: Burkitt's lymphoma

tag: passages


title: RCC sample pre vaccination #4

description: primary RCC sample, before vaccination


title: Cutaneous psoriasis without arthritis PsC 11

description: Biological replicate 11 of 20.

tag: gender


title: Cutaneous psoriasis without arthritis PsC 10

description: Biological replicate 10 of 20.

value: Male


title: Cutaneous psoriasis without arthritis PsC 9

description: Biological replicate 9 of 20.


title: RCC sample pre vaccination #3

description: primary RCC sample, before vaccination


title: Cutaneous psoriasis without arthritis PsC 7

description: Biological replicate 7 of 20.


title: iPS-MSC_M2C6_d7 [Methylation]

tag: cell type

value: iPS-MSC

value: passage 0


title: Cutaneous psoriasis without arthritis PsC 8

description: Biological replicate 8 of 20.

value: Cutaneous psoriasis without arthritis


title: Cutaneous psoriasis without arthritis PsC 5

description: Biological replicate 5 of 20.


title: RCC sample pre vaccination #2

description: primary RCC sample, before vaccination


title: iPSC_M2C6 [Methylation]


title: RCC sample pre vaccination #5

description: primary RCC sample, before vaccination


title: Cutaneous psoriasis without arthritis PsC 12

description: Biological replicate 12 of 20.


title: RCC sample post vaccination #9

description: primary RCC sample, after vaccination

value: after vaccination


title: Cutaneous psoriasis without arthritis PsC 4

description: Biological replicate 4 of 20.


title: L428 DNA methylation

source_name: Hodgkin's Lymphoma cell line

value: Hodgkin's Lymphoma


title: RCC sample post vaccination #4

description: primary RCC sample, after vaccination


title: L1236 DNA methylation


title: RCC sample post vaccination #6

description: primary RCC sample, after vaccination


title: iPS-MSC_M4C4_d35 [Methylation]

value: donor 4; clone 4

value: passage 4


title: Cutaneous psoriasis without arthritis PsC 2

description: Biological replicate 2 of 20.


title: RCC sample post vaccination #8

description: primary RCC sample, after vaccination


title: RCC sample post vaccination #5

description: primary RCC sample, after vaccination


title: RCC sample post vaccination #7

description: primary RCC sample, after vaccination


title: RCC sample pre vaccination #1

description: primary RCC sample, before vaccination

value: before vaccination


title: Cutaneous psoriasis without arthritis PsC 1

description: Biological replicate 1 of 20.


title: RCC sample post vaccination #3

description: primary RCC sample, after vaccination


title: Psoriatic arthritis PsA 19

description: Biological replicate 19 of 20.

value: Psoriatic arthritis


title: iPS-MSC_M2C6_d14 [Methylation]

value: donor 2; clone 6

value: passage 1


title: RCC sample post vaccination #2

description: primary RCC sample, after vaccination


title: Psoriatic arthritis PsA 20

description: Biological replicate 20 of 20.

value: whole blood


title: Cutaneous psoriasis without arthritis PsC 3

description: Biological replicate 3 of 20.


title: Psoriatic arthritis PsA 18

description: Biological replicate 18 of 20.


title: RCC sample post vaccination #1

description: primary RCC sample, after vaccination


title: healthy control array #9

description: independent healthy control sample

value: healthy control


title: Psoriatic arthritis PsA 16

description: Biological replicate 16 of 20.

value: Female

value: 10 human cell lines:Adenocarcinoma, mammary gland; Hepatoblastoma, liver; Adenocarcinoma, cervix; Embryonal carcinoma, testis; Glioblastoma, brain; Melanoma; Liposarcoma; Histiocytic lymphoma, macrophage, histocyte; Lymphoblastic leukemia, T lymphoblast; Plasmacytoma, myeloma, B lymphocyte


title: Psoriatic arthritis PsA 15

description: Biological replicate 15 of 20.


title: Psoriatic arthritis PsA 17

description: Biological replicate 17 of 20.


title: Cutaneous psoriasis without arthritis PsC 6

description: Biological replicate 6 of 20.


title: healthy control array #8

description: independent healthy control sample


title: Reh3 IRF.CEL

city: Berlin

first: Karl

last: Koechert

address: Robert-Roessle-Str. 10

institute: Max-Delbrueck-Centre for Molecular Medicine

hyb_protocol: Hybridization was done according to the manufacturer's recommendations (Affymetrix).

scan_protocol: Scanning was done according to the manufacturer's recommendations (Affymetrix). Scanner Model was GeneChip® Scanner 3000 7G, GeneChip® Command Console® 2.0.1 was used as software.

data_processing: Raw data were background corrected with RMA and normalized using quantile normalization. All processeing was done in R/Bioconductor.

source_name: Reh3 IRF

label_protocol: Labeling was done according to the manufacturer's recommendations (Affymetrix).

extract_protocol: Total RNA was extracted using RNeasy Mini-Kit from QIAGEN according to the manufacturer's recommendations.

value: Reh

tag: transfection

value: IRF


title: Psoriatic arthritis PsA 14

description: Biological replicate 14 of 20.


title: healthy control array #7

description: independent healthy control sample


title: healthy control array #5

description: independent healthy control sample


title: Reh3 IKK.CEL

source_name: Reh3 IKK

value: IKK


title: Psoriatic arthritis PsA 13

description: Biological replicate 13 of 20.


title: healthy control array #6

description: independent healthy control sample


title: Reh3-Mock.CEL

source_name: Reh3 Mock

value: Mock


title: Psoriatic arthritis PsA 12

description: Biological replicate 12 of 20.


title: Reh1-Mock.CEL

source_name: Reh1 Mock


title: Reh1 IRF.CEL

source_name: Reh1 IRF


title: Reh1 IRF54D_IKK.CEL

source_name: Reh1 IRF54D_IKK


title: Psoriatic arthritis PsA 9

description: Biological replicate 9 of 20.

value: Male


title: healthy control array #4

description: independent healthy control sample


title: Reh3 IRF54D_IKK.CEL

source_name: Reh3 IRF54D_IKK


title: healthy control array #3

description: independent healthy control sample


title: healthy control array #2

description: independent healthy control sample


title: Psoriatic arthritis PsA 10

description: Biological replicate 10 of 20.


title: Psoriatic arthritis PsA 11

description: Biological replicate 11 of 20.


title: healthy control array #1

description: independent healthy control sample


title: RCC sample pre vaccination #6

description: primary RCC sample, before vaccination


title: control3

description: control

hyb_protocol: Hybridization was done according to the manufacturer's recommendations (Illumina).

scan_protocol: Arrays were scanned on a Bead Array Reader according to the manufacturers recommendations (Illumina).

data_processing: Background correction was done according to Illuminas proprietary correction algorithm, and data were normalized using quantile normalization. All processing was done using R package beadarray, which does not give any detection p values.

organism: Mus musculus

source_name: murine splenic b cells control

label_protocol: Labeling was done according to the manufacturer's recommendations (Illumina).

tag: strain

value: splenic B-cells

tag: transduction

value: control


title: Psoriatic arthritis PsA 6

description: Biological replicate 6 of 20.


title: IRF52

source_name: murine splenic b cells IRF5


title: Psoriatic arthritis PsA 8

description: Biological replicate 8 of 20.


title: Psoriatic arthritis PsA 5

description: Biological replicate 5 of 20.


title: Reh1 IKK.CEL

source_name: Reh1 IKK


title: Reh DNA Methylation

source_name: Pro-B lymphoblastic leukemia cell line

value: Pro-B lymphoblastic leukemia


title: Psoriatic arthritis PsA 7

description: Biological replicate 7 of 20.

source_name: Whole blood


title: control2

description: control


title: Parent line, biological rep3

city: Davis

first: Katayoon

last: Dehesh

state: CA

address: One Shilels Avenue

department: Plant Biology

institute: UNIVERSITY OF CALIFORNIA DAVIS

hyb_protocol: Following fragmentation, 10 µg of biotinylated cRNA were hybridized to Affymetrix chips (Arabidopsis ATH1 Genome Array). Each sample was added to a hybridization solution containing 100mM 2-(N-morpholino)ethanesulfonic acid, 1 M Na+, and 20mM of EDTA in the presence of 0.01% of Tween-20 to a final cRNA concentration of 0.05 µg/ml. Hybridization was performed for 16 h at 45ºC . Each microarray was washed and stained with streptavidin-phycoerythrin in a Fluidics station 450 (Affymetrix).

scan_protocol: GeneChips were scanned using the standard Affymetrix GeneChip Scanner

data_processing: The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100.

organism: Arabidopsis thaliana

source_name: 2 week old plants on 1/2 MS medium

label_protocol: Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 4 µg total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

growth_protocol: Arabidopsis thaliana ceh1 mutant and corresponding parent line seeds were plated on ½ MS medium and kept at 4°C for 2 days, then the plants were grown in a growth chamber for 2 weeks with a light intensity of approximately 100-150 µE m-2s-1 at 23°C under 8 h light/16 h dark cycles and 60% humidity.

extract_protocol: RNA was isolated with Trizol (Invitrogen) followed by the RNA purification using RNeasy Plant Mini Kit (Qiagen) following manufacture´s instructions.

tag: genotype

value: Parent of line ceh1 mutant (Wild Type)


title: control1

description: control


title: IRF53


title: ceh1 mutant, biological rep2

value: ceh1 mutant


title: ceh1 mutant, biological rep1


title: IRF51


title: Parent line, biological rep2


title: ceh1 mutant, biological rep3


title: Psoriatic arthritis PsA 1

description: Biological replicate 1 of 20.

value: Psoriatic arthritis

source_name: Human Universal Reference RNA (Stratagene)


title: Psoriatic arthritis PsA 2

description: Biological replicate 2 of 20.


title: Parent line, biological rep1


title: Psoriatic arthritis PsA 4

description: Biological replicate 4 of 20.


title: ALDH_negative_MCF

status: Public on Sep 23 2014

city: Setagaya-ku

first: Yasunari

last: Kanda

state: Tokyo

address: 1-18-1 Kamiyoga

department: Division of Pharmacology

country: Japan

institute: National Institute of Health Sciences

description: ALDH negative

hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45 degrees on GeneChip. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.

scan_protocol: GeneChips were scanned using GeneChip Scanner 3000 7G

data_processing: Single Array Analysis were calculated by  Microarray Suite version 5.0 (MAS5.0) with Affymetrix default setting and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 500.

source_name: ALDH negative cell population from MCF-7 cells

label_protocol: Biotinylated cRNA were synthesized by GeneChip 3'IVT Express Kit（Affymetrix) from 250 ng total RNA.

growth_protocol: MCF-7 cells were maintained in a normal condition.

extract_protocol: RNeasy extraction of total RNA was performed according to the manufacturer's instructions.

treatment_protocol: ALDEFLUOR assay was performed using MCF-7 cells, according to the manufacture's protocol. ALDH-positive and negative cell population were sorted using FACS Aria II and subjected to RNA isolation.

tag: cell population


title: Psoriatic arthritis PsA 3

description: Biological replicate 3 of 20.

tag: tissue


title: shpkp3-2-2

city: navi mumbai

first: Srikanta

last: Basu

state: Maharashtra

address: Kharghar, sector 22

department: Sorab's Lab

country: India

institute: TMC-ACTREC

description: Gene expression of FBM derived plakophilin3 knockdown clone

hyb_protocol: 1.5 ug of Cy3-labelled cRNA (specific activity >10.0 pmol Cy3/ug cRNA) was fragmented at 60°C for 30 minutes in a reaction volume of 250 ml containing 1x Agilent fragmentation buffer and 2x Agilent blocking agent following the manufacturers instructions. On completion of the fragmentation reaction, 250 ml of 2x Agilent hybridization buffer was added to the fragmentation mixture and hybridized to Agilent Whole Human Genome Oligo Microarray ( Design, Agilent-027114; platform GPL13252) for 17 hours at 65°C in a rotating Agilent hybridization oven.  After hybridization, microarrays were washed 1 minute at room temperature with GE Wash Buffer 1 (Agilent) and 1 minute with 37°C GE Wash buffer 2 (Agilent), then dried immediately by brief centrifugation.

scan_protocol: Slides were scanned immediately after washing on the Agilent DNA Microarray Scanner (Agilent SureScan microarray scanner, G2505C US83000164) using one color scan setting for 8x60k array slides (Scan Area 61x21.6 mm; Scan resolution 5um, Single pass; Dye channel is set to Green and Green PMT is set to XDR High 100% and XDR Low 10%).

data_processing: The scanned images were analyzed using the Automated feature extraction using Agilent Feature Extraction software (9.1). Normalization and statistical analysis, Pathway and Gene Ontology analysis was performed using Agilent's GeneSpring GX v 11.0 and Genotypic's Biointerpreter Software.

source_name: Cells, PKP3 knockdown biological replicate 2

label_protocol: Cy3 Labeling (Single color) was done using Agilent's Quick Amp kit (cDNA synthesis and in vitro transcription)

growth_protocol: Cells were grown in Iscove's modified DMEM medium (IMDM) and plasmid encoding shRNA agiainst plakophilin3 was maintained in cells (stable clones) by using 5μg/ml puromycin selection

extract_protocol: RNA was extracted using by column method using the Qiagen Rneasy Plus Mini kit (Cat. No. 74134) in RNase free, Non-DEPC treated water (Invitrogen, Cat#10977015, Ambion).Samples were packed in nuclease-free microtubes secured with parafilm or screw capped tubes.  Samples were sent in dry ice from Dr. Sorab's Lab, TMC-ACTREC, Navi Mumbai, India to Genotypic, Bangalore, India, for further processing of the samples.

treatment_protocol: Plakophilin3 was knocked down using using stable transfection of plasmid encoded shRNA.

value: FBM

tag: cell line origin

value: fetal buccal mucosa derived


title: vec1

description: Gene expression of FBM derived vector control

source_name: Cells,vector control,biological replicate 1


title: patient 98, tumor sub-sample D

city: Heidelberg

last: Meister

state: Select One

address: Roentgenstr. 1

department: STF

institute: Thoraxklinik-Heidelberg

hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45°C on Affymetrix U133 Plus 2.0. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.

scan_protocol: GeneChips were scanned using the Affymetrix GeneChip Scanner 3000.

data_processing: Bioconductor [Gentleman et al. Genome Biology 2004] and R language [Ihaka and Gentleman. Journal of Computational and Graphical Statistics 1996] were used for pre-processing of the hybridizations. The microarray data was normalized and gene expression summarized by the RMA-PLM method [Bolstad et al. Quality Assessment of Affymetrix GeneChip Data in Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Springer 2005]. All probes on the Affymetrix HG-U133 Plus 2.0 microarray were re-evaluated through a systematic comparison of probe sequences with reference sequence databases (RefSeq, EMBL, UniGene) and the available genome drafts. Out of 56,675 initial probe sets 25,906 high quality & expressed probe sets were considered for further analysis. Probe Level Model (PLM) algorithm was used to fit probe-intensity data and estimate expression of the probe sets. These considered probe sets unambiguously matched known loci, and showed expression that exceeded the estimated limit of blank (LOB) in at least 4 samples out of 100. The limit of blank value (which was estimated to be 5.5 on log2 scale) was defined as the 95% percentile of the expression of the ‘complete mismatch’ probe sets. The ‘complete mismatch’ probe sets were composed of the probes that failed to match both genomic sequence as well as known mRNA and EST transcripts even when up to 3 mismatches were tolerated. The disregarded probe sets were not considered in statistical analyses relevant for our manuscript.

source_name: human non-small cell lung cancer tissue

label_protocol: Double stranded cDNA was synthesized from  5 ug total RNA with a Microarray cDNA Synthesis Kit, Roche, Mannheim, Germany, according to the manufactures protocol. Biotinylated cRNA were prepared according to the standard Affymetrix protocol (GeneChip Expression 3´-Amplification IVT Labeling Kit and GeneChip Sample Cleanup Module, Affymetrix)).

extract_protocol: For RNA extraction 10 - 15 cryo sections (10 - 15 µm each) of tissue sub-blocks derived from 4 different areas of the tumor were prepared for each patient.The first and the last section of the series were stained with Hematoxylin and Eosin and were reviewed by the study pathologist to determine the proportion of viable tumor cell, stromal cell, normal lung cell content, infiltrating lymphocytes and necrotic areas.Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturers’ instructions

treatment_protocol: Each tumor was cut into 4 approximately equal sized tissue blocks, subsequently fragmented into sub-blocks of about 125 mm³, snap-frozen within 30 minutes after resection and stored at -80°C. Matched normal lung tissues were snap-frozen within 30 minutes after resection and stored at -80°C

value: male

tag: age

value: lung

tag: histology

value: mixed


title: shpkp3-2-1

source_name: Cells, PKP3 knockdown biological replicate 1


title: patient 93, tumor sub-sample D

value: squamous


title: patient 98, matched normal lung

source_name: human, normal lung tissue

value: normal lung


title: patient 98, tumor sub-sample A


title: vec2

source_name: Cells,vector control,biological replicate 2


title: patient 98, tumor sub-sample C


title: patient 93, matched normal lung


title: patient 93, tumor sub-sample A


title: patient 93, tumor sub-sample C


title: ALDH_positive_MCF

description: ALDH positive

source_name: ALDH positive cell population from MCF-7 cells

value: ALDH-positive


title: patient 98, tumor sub-sample B


title: patient 85, tumor sub-sample D


title: patient 93, tumor sub-sample B


title: patient 85, matched normal lung


title: patient 62, matched normal lung


title: patient 85, tumor sub-sample C


title: patient 85, tumor sub-sample A


title: patient 62, tumor sub-sample B

value: adeno


title: patient 85, tumor sub-sample B


title: patient 62, tumor sub-sample C


title: patient 59, tumor sub-sample C


title: patient 62, tumor sub-sample D


title: patient 59, tumor sub-sample D


title: patient 59, matched normal lung


title: patient 62, tumor sub-sample A


title: patient 59, tumor sub-sample B


title: patient 59, tumor sub-sample A


title: patient 58, tumor sub-sample B

value: female


title: patient 58, tumor sub-sample A


title: patient 57, tumor sub-sample B


title: patient 57, matched normal lung


title: patient 58, matched normal lung


title: patient 43, tumor sub-sample D


title: patient 57, tumor sub-sample D


title: patient 58, tumor sub-sample D


title: patient 43, tumor sub-sample B


title: patient 58, tumor sub-sample C


title: patient 57, tumor sub-sample A


title: patient 43, tumor sub-sample A


title: patient 57, tumor sub-sample C


title: patient 42, tumor sub-sample B


title: patient 43, tumor sub-sample C


title: patient 42, tumor sub-sample C


title: patient 42, tumor sub-sample A


title: patient 41, tumor sub-sample C


title: patient 43, matched normal lung


title: patient 42, matched normal lung


title: patient 41, matched normal lung


title: patient 34, tumor sub-sample D


title: patient 41, tumor sub-sample D


title: patient 42, tumor sub-sample D


title: patient 34, tumor sub-sample C


title: patient 41, tumor sub-sample B


title: patient 34, matched normal lung


title: patient 41, tumor sub-sample A


title: patient 28, tumor sub-sample D


title: patient 28, matched normal lung


title: patient 34, tumor sub-sample A


title: patient 28, tumor sub-sample C


title: patient 27, tumor sub-sample B


title: patient 27, tumor sub-sample D


title: patient 28, tumor sub-sample B


title: patient 34, tumor sub-sample B


title: patient 27, tumor sub-sample C


title: patient 11, tumor sub-sample D


title: patient 17, tumor sub-sample D


title: patient 17, tumor sub-sample C


title: patient 22, tumor sub-sample B


title: patient 17, tumor sub-sample B


title: patient 11, tumor sub-sample C


title: patient 11, matched normal lung


title: patient 11, tumor sub-sample B


title: patient 27, tumor sub-sample A


title: patient 27, matched normal lung


title: patient 22, tumor sub-sample C


title: patient 28, tumor sub-sample A


title: patient 22, tumor sub-sample A


title: patient 17, matched normal lung


title: patient 22, tumor sub-sample D


title: patient 10, tumor sub-sample C


title: Control 156

city: Birmingham

first: Christine

middle: F

last: Skibola

state: AL

address: 1665 University Boulevard

institute: University of Alabama at Birmingham

hyb_protocol: Standard Illumina protocol

scan_protocol: Standard Illumina protocol

data_processing:
Log R ratios and B allele frequency values were exported from the Beadstudio software (Illumina)
Log R ratios and B allele frequecies for the 619 NHL cases and 730 controls that passed quality control criteria.

label_protocol: Standard Illumina protocol

extract_protocol: Genomic DNA from cases and controls was extracted from whole blood using QIAamp DNA Blood Maxi Kit protocol (Qiagen, Valencia, CA) and quantified using PicoGreen dsDNAQuantitation kits (Invitrogen, Carlsbad, CA) according to the manufacturers’ specifications

tag: nhl subtype

value: Control


title: Control 155


title: patient 10, tumor sub-sample D


title: patient 08, tumor sub-sample D


title: patient 10, tumor sub-sample B


title: patient 11, tumor sub-sample A


title: patient 22, matched normal lung


title: patient 10, matched normal lung


title: patient 10, tumor sub-sample A


title: patient 17, tumor sub-sample A


title: patient 07, tumor sub-sample D


title: patient 08, tumor sub-sample C


title: patient 08, matched normal lung


title: patient 08, tumor sub-sample B


title: patient 07, tumor sub-sample C


title: Control 154


title: patient 02, tumor sub-sample D


title: patient 07, tumor sub-sample B


title: patient 02, tumor sub-sample C


title: Control 153


title: Control 152


title: Control 151


title: Control 150


title: patient 07, matched normal lung


title: patient 08, tumor sub-sample A


title: patient 02, matched normal lung


title: Control 149


title: patient 02, tumor sub-sample A


title: patient 07, tumor sub-sample A


title: Control 148


title: HEK293_hCdc73siRNASparse_rep1

city: Pohang

first: Jay-Hyun

last: Jo

state: Gyeongbuk

address: 77 Cheongam-Ro. Nam-Gu

department: Life Science

country: South Korea

description: replicate 1

hyb_protocol: Standard Illumina hybridization protocol

scan_protocol: Standard Illumina scanning protocol

data_processing: The data were normalised using quantile normalisation with IlluminaGUI in R

label_protocol: Biotinylated cRNA were prepared with the Ambion MessageAmp kit for Illumina arrays

growth_protocol: DMEM supplemented with 10% FBS, 1% pen/strep.

extract_protocol: Total RNA was purified with an RNeasy Kit (Qiagen, Valencia, CA) and was amplified using a TotalPrep RNA Amplification Kit (Ambion, Austin, TX).

treatment_protocol: 100pmol siRNA was transfected to 5X10^5 HEK293 cells, and 24hours after sparse cells were moved onto 100mm dish, and confluent cells were moved onto 35mm dish. Cells were harvested after additional 24hours.

tag: sirna

tag: condition

value: sparse


title: Control 147


title: HEK293_hCdc73siRNAConfluent_rep1

description: replicate 1

value: confluent cell density


title: HEK293_ControlsiRNASparse_rep1

description: replicate 1

value: control


title: Control 146


title: HEK293_ControlsiRNAConfluent_rep1

description: replicate 1


title: Control 143


title: patient 02, tumor sub-sample B


title: Control 141


title: Control 140


title: Control 137


title: Control 136


title: Control 134


title: Control 132


title: Control 131


title: Control 145


title: Control 130


title: Control 128


title: Control 138


title: Control 127


title: Control 129


title: Control 126


title: Control 124


title: Control 125


title: Control 123


title: Control 120


title: Control 142


title: Control 118


title: Control 117


title: Control 144


title: Control 122


title: Control 135


title: Control 116


title: Control 113


title: Control 114


title: Control 112


title: Control 115


title: Control 133


title: Control 111


title: Control 110


title: Control 107


title: Control 106


title: Control 104


title: Control 103


title: Control 101


title: Control 102


title: Control 105


title: Control 100


title: Control 98


title: Control 119


title: Control 97


title: Control 93


title: Control 99


title: Control 94


title: Control 95


title: Control 108


title: Control 96


title: Control 91


title: Control 90


title: Control 121


title: Control 89


title: Control 85


title: Control 88


title: Control 86


title: Control 109


title: Control 84


title: Control 83


title: Control 82


title: Control 80


title: Control 87


title: Control 76


title: Control 77


title: Control 75


title: Control 92


title: Control 73


title: Control 70


title: Control 69


title: Control 68


title: Control 71


title: Control 78


title: Control 65


title: Control 63


title: Control 74


title: Control 66


title: Control 60


title: Control 59


title: Control 61


title: Control 56


title: Control 81


title: Control 62


title: Control 55


title: Control 58


title: Control 64


title: Control 54


title: Control 79


title: Control 57


title: Control 52


title: Control 53


title: Control 72


title: Control 51


title: Control 50


title: Control 49


title: Control 48


title: Control 47


title: Control 67


title: Control 44


title: Control 45


title: Control 40


title: Control 39


title: Control 38


title: Control 37


title: Control 36


title: Control 35


title: Control 41


title: Control 42


title: Control 34


title: Control 31


title: Control 30


title: Control 32


title: Control 28


title: Control 27


title: Control 25


title: Control 23


title: Control 22


title: Control 24


title: Control 21


title: Control 20


title: Control 46


title: Control 18


title: Control 19


title: Control 43


title: Control 17


title: Control 16


title: Control 15


title: Control 14


title: Control 11


title: Control 10


title: Control 9


title: Control 33


title: Control 8


title: Control 7


title: Control 12


title: Control 5


title: Control 6


title: Control 26


title: Control 4


title: Control 3


title: Control 2


title: Control 29


title: Control 1


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 170

value: CLL/SLL


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 169


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 168


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 172


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 167


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 166


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 171


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 165


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 163


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 162


title: Control 13


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 164


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 161


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 160


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 159


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 155


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 156


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 157


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 153


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 154


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 152


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 151


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 149


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 150


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 148


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 146


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 145


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 142


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 143


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 144


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 141


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 138


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 136


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 135


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 140


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 139


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 134


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 137


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 132


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 131


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 130


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 133


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 158


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 128


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 129


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 127


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 125


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 126


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 124


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 147


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 121


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 123


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 120


title: Control 139


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 117


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 119


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 116


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 114


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 115


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 113


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 118


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 111


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 110


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 109


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 108


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 106


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 107


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 112


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 105


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 102


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 100


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 103


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 97


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 98


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 104


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 101


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 99


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 96


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 122


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 93


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 94


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 95


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 92


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 91


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 90


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 88


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 89


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 87


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 86


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 85


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 84


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 83


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 81


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 80


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 82


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 79


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 77


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 76


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 75


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 73


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 72


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 71


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 74


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 70


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 68


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 69


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 67


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 66


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 65


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 64


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 63


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 61


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 62


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 58


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 60


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 59


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 56


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 55


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 78


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 52


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 50


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 51


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 48


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 47


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 46


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 45


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 39


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 41


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 42


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 40


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 43


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 44


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 37


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 35


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 36


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 32


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 29


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 57


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 28


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 53


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 34


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 31


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 54


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 26


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 30


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 25


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 23


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 24


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 49


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 22


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 21


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 20


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 38


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 19


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 18


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 17


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 15


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 12


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 33


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 16


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 11


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 14


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 9


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 10


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 8


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 7


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 6


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 27


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 4


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 1


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 3


title: Diffusse large B-cell Lymphoma 239

value: DLBCL


title: Diffusse large B-cell Lymphoma 238


title: Diffusse large B-cell Lymphoma 241


title: Diffusse large B-cell Lymphoma 242


title: Diffusse large B-cell Lymphoma 235


title: Diffusse large B-cell Lymphoma 234


title: Diffusse large B-cell Lymphoma 233


title: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 13


title: Diffusse large B-cell Lymphoma 229


title: Diffusse large B-cell Lymphoma 230


title: Diffusse large B-cell Lymphoma 232


title: Diffusse large B-cell Lymphoma 226


title: Diffusse large B-cell Lymphoma 228


title: Diffusse large B-cell Lymphoma 225


title: Diffusse large B-cell Lymphoma 224


title: Diffusse large B-cell Lymphoma 222


title: Diffusse large B-cell Lymphoma 223


title: Diffusse large B-cell Lymphoma 221


title: Diffusse large B-cell Lymphoma 218


title: Diffusse large B-cell Lymphoma 220


title: Diffusse large B-cell Lymphoma 240


title: Diffusse large B-cell Lymphoma 219


title: Diffusse large B-cell Lymphoma 216


title: Diffusse large B-cell Lymphoma 215


title: Diffusse large B-cell Lymphoma 217


title: Diffusse large B-cell Lymphoma 214


title: Diffusse large B-cell Lymphoma 212


title: Diffusse large B-cell Lymphoma 237


title: Diffusse large B-cell Lymphoma 236


title: Diffusse large B-cell Lymphoma 213


title: Diffusse large B-cell Lymphoma 211


title: Diffusse large B-cell Lymphoma 209


title: Diffusse large B-cell Lymphoma 208


title: Diffusse large B-cell Lymphoma 231


title: Diffusse large B-cell Lymphoma 227


title: Diffusse large B-cell Lymphoma 207


title: Diffusse large B-cell Lymphoma 206


title: Diffusse large B-cell Lymphoma 205


title: Diffusse large B-cell Lymphoma 202


title: Diffusse large B-cell Lymphoma 203


title: Diffusse large B-cell Lymphoma 200


title: Diffusse large B-cell Lymphoma 199


title: Diffusse large B-cell Lymphoma 196


title: Diffusse large B-cell Lymphoma 195


title: Diffusse large B-cell Lymphoma 194


title: Diffusse large B-cell Lymphoma 190


title: Diffusse large B-cell Lymphoma 192


title: Diffusse large B-cell Lymphoma 210


title: Diffusse large B-cell Lymphoma 191


title: Diffusse large B-cell Lymphoma 193


title: Diffusse large B-cell Lymphoma 185


title: Diffusse large B-cell Lymphoma 188


title: Diffusse large B-cell Lymphoma 182


title: Diffusse large B-cell Lymphoma 183


title: Diffusse large B-cell Lymphoma 186


title: Diffusse large B-cell Lymphoma 201


title: Diffusse large B-cell Lymphoma 184


title: Diffusse large B-cell Lymphoma 187


title: Diffusse large B-cell Lymphoma 180


title: Diffusse large B-cell Lymphoma 181


title: Diffusse large B-cell Lymphoma 178


title: Diffusse large B-cell Lymphoma 177


title: Diffusse large B-cell Lymphoma 176


title: Diffusse large B-cell Lymphoma 175


title: Diffusse large B-cell Lymphoma 204


title: Diffusse large B-cell Lymphoma 179


title: Diffusse large B-cell Lymphoma 174


title: Diffusse large B-cell Lymphoma 197


title: Diffusse large B-cell Lymphoma 198


title: Diffusse large B-cell Lymphoma 171


title: Diffusse large B-cell Lymphoma 165


title: Diffusse large B-cell Lymphoma 166


title: Diffusse large B-cell Lymphoma 167


title: Diffusse large B-cell Lymphoma 164


title: Diffusse large B-cell Lymphoma 189


title: Diffusse large B-cell Lymphoma 168


title: Diffusse large B-cell Lymphoma 170


title: Diffusse large B-cell Lymphoma 162


title: Diffusse large B-cell Lymphoma 163


title: Diffusse large B-cell Lymphoma 161


title: Diffusse large B-cell Lymphoma 156


title: Diffusse large B-cell Lymphoma 159


title: Diffusse large B-cell Lymphoma 158


title: Diffusse large B-cell Lymphoma 157


title: Diffusse large B-cell Lymphoma 155


title: Diffusse large B-cell Lymphoma 153


title: Diffusse large B-cell Lymphoma 173


title: Diffusse large B-cell Lymphoma 152


title: Diffusse large B-cell Lymphoma 149


title: Diffusse large B-cell Lymphoma 151


title: Diffusse large B-cell Lymphoma 148


title: Diffusse large B-cell Lymphoma 147


title: Diffusse large B-cell Lymphoma 172


title: Diffusse large B-cell Lymphoma 154


title: Diffusse large B-cell Lymphoma 146


title: Diffusse large B-cell Lymphoma 145


title: Diffusse large B-cell Lymphoma 150


title: Diffusse large B-cell Lymphoma 169


title: Diffusse large B-cell Lymphoma 144


title: Diffusse large B-cell Lymphoma 160


title: Diffusse large B-cell Lymphoma 143


title: Diffusse large B-cell Lymphoma 140


title: Diffusse large B-cell Lymphoma 139


title: Diffusse large B-cell Lymphoma 141


title: Diffusse large B-cell Lymphoma 142


title: Diffusse large B-cell Lymphoma 135


title: Diffusse large B-cell Lymphoma 132


title: Diffusse large B-cell Lymphoma 136


title: Diffusse large B-cell Lymphoma 134


title: Diffusse large B-cell Lymphoma 133


title: Diffusse large B-cell Lymphoma 131


title: Diffusse large B-cell Lymphoma 137


title: Diffusse large B-cell Lymphoma 129


title: Diffusse large B-cell Lymphoma 138


title: Diffusse large B-cell Lymphoma 125


title: Diffusse large B-cell Lymphoma 126


title: Diffusse large B-cell Lymphoma 124


title: Diffusse large B-cell Lymphoma 127


title: Diffusse large B-cell Lymphoma 123


title: Diffusse large B-cell Lymphoma 121


title: Diffusse large B-cell Lymphoma 120


title: Diffusse large B-cell Lymphoma 119


title: Diffusse large B-cell Lymphoma 118


title: Diffusse large B-cell Lymphoma 116


title: Diffusse large B-cell Lymphoma 115


title: Diffusse large B-cell Lymphoma 114


title: Diffusse large B-cell Lymphoma 113


title: Diffusse large B-cell Lymphoma 111


title: Diffusse large B-cell Lymphoma 112


title: Diffusse large B-cell Lymphoma 109


title: Diffusse large B-cell Lymphoma 108


title: Diffusse large B-cell Lymphoma 110


title: Diffusse large B-cell Lymphoma 130


title: Diffusse large B-cell Lymphoma 107


title: Diffusse large B-cell Lymphoma 128


title: Diffusse large B-cell Lymphoma 104


title: Diffusse large B-cell Lymphoma 102


title: Diffusse large B-cell Lymphoma 105


title: Diffusse large B-cell Lymphoma 101


title: Diffusse large B-cell Lymphoma 99


title: Diffusse large B-cell Lymphoma 100


title: Diffusse large B-cell Lymphoma 103


title: Diffusse large B-cell Lymphoma 98


title: Diffusse large B-cell Lymphoma 97


title: Diffusse large B-cell Lymphoma 122


title: Diffusse large B-cell Lymphoma 96


title: Diffusse large B-cell Lymphoma 95


title: Diffusse large B-cell Lymphoma 94


title: Diffusse large B-cell Lymphoma 93


title: Diffusse large B-cell Lymphoma 92


title: Diffusse large B-cell Lymphoma 91


title: Diffusse large B-cell Lymphoma 117


title: Diffusse large B-cell Lymphoma 90


title: Diffusse large B-cell Lymphoma 89


title: Diffusse large B-cell Lymphoma 87


title: Diffusse large B-cell Lymphoma 86


title: Diffusse large B-cell Lymphoma 106


title: Diffusse large B-cell Lymphoma 85


title: Diffusse large B-cell Lymphoma 88


title: Diffusse large B-cell Lymphoma 84


title: Diffusse large B-cell Lymphoma 82


title: Diffusse large B-cell Lymphoma 78


title: Diffusse large B-cell Lymphoma 81


title: Diffusse large B-cell Lymphoma 83


title: Diffusse large B-cell Lymphoma 80


title: Diffusse large B-cell Lymphoma 79


title: Diffusse large B-cell Lymphoma 75


title: Diffusse large B-cell Lymphoma 74


title: Diffusse large B-cell Lymphoma 71


title: Diffusse large B-cell Lymphoma 73


title: Diffusse large B-cell Lymphoma 72


title: Diffusse large B-cell Lymphoma 70


title: Diffusse large B-cell Lymphoma 69


title: Diffusse large B-cell Lymphoma 77


title: Diffusse large B-cell Lymphoma 68


title: Diffusse large B-cell Lymphoma 67


title: Diffusse large B-cell Lymphoma 63


title: Diffusse large B-cell Lymphoma 65


title: Diffusse large B-cell Lymphoma 64


title: Diffusse large B-cell Lymphoma 66


title: Diffusse large B-cell Lymphoma 62


title: Diffusse large B-cell Lymphoma 61


title: Diffusse large B-cell Lymphoma 57


title: Diffusse large B-cell Lymphoma 56


title: Diffusse large B-cell Lymphoma 58


title: Diffusse large B-cell Lymphoma 55


title: Diffusse large B-cell Lymphoma 60


title: Diffusse large B-cell Lymphoma 53


title: Diffusse large B-cell Lymphoma 48


title: Diffusse large B-cell Lymphoma 49


title: Diffusse large B-cell Lymphoma 52


title: Diffusse large B-cell Lymphoma 76


title: Diffusse large B-cell Lymphoma 54


title: Diffusse large B-cell Lymphoma 51


title: Diffusse large B-cell Lymphoma 45


title: Diffusse large B-cell Lymphoma 43


title: Diffusse large B-cell Lymphoma 40


title: Diffusse large B-cell Lymphoma 39


title: Diffusse large B-cell Lymphoma 47


title: Diffusse large B-cell Lymphoma 46


title: Diffusse large B-cell Lymphoma 38


title: Diffusse large B-cell Lymphoma 41


title: Diffusse large B-cell Lymphoma 50


title: Diffusse large B-cell Lymphoma 37


title: Diffusse large B-cell Lymphoma 35


title: Diffusse large B-cell Lymphoma 36


title: Diffusse large B-cell Lymphoma 33


title: Diffusse large B-cell Lymphoma 34


title: Diffusse large B-cell Lymphoma 44


title: Diffusse large B-cell Lymphoma 32


title: Diffusse large B-cell Lymphoma 59


title: Diffusse large B-cell Lymphoma 29


title: Diffusse large B-cell Lymphoma 27


title: Diffusse large B-cell Lymphoma 30


title: Diffusse large B-cell Lymphoma 28


title: Diffusse large B-cell Lymphoma 26


title: Diffusse large B-cell Lymphoma 23


title: Diffusse large B-cell Lymphoma 25


title: Diffusse large B-cell Lymphoma 24


title: Diffusse large B-cell Lymphoma 42


title: Diffusse large B-cell Lymphoma 22


title: Diffusse large B-cell Lymphoma 21


title: Diffusse large B-cell Lymphoma 20


title: Diffusse large B-cell Lymphoma 17


title: Diffusse large B-cell Lymphoma 18


title: Diffusse large B-cell Lymphoma 16


title: Diffusse large B-cell Lymphoma 12


title: Diffusse large B-cell Lymphoma 19


title: Diffusse large B-cell Lymphoma 13


title: Diffusse large B-cell Lymphoma 8


title: Diffusse large B-cell Lymphoma 10


title: Diffusse large B-cell Lymphoma 15


title: Diffusse large B-cell Lymphoma 11


title: Diffusse large B-cell Lymphoma 14


title: Diffusse large B-cell Lymphoma 5


title: Diffusse large B-cell Lymphoma 9


title: Diffusse large B-cell Lymphoma 6


title: Diffusse large B-cell Lymphoma 4


title: Diffusse large B-cell Lymphoma 7


title: Diffusse large B-cell Lymphoma 3


title: Diffusse large B-cell Lymphoma 1


title: Diffusse large B-cell Lymphoma 2


title: Follicular Lymphoma 205

value: FL


title: Follicular Lymphoma 204


title: Follicular Lymphoma 203


title: Follicular Lymphoma 202


title: Follicular Lymphoma 200


title: Follicular Lymphoma 199


title: Follicular Lymphoma 198


title: Follicular Lymphoma 197


title: Follicular Lymphoma 196


title: Follicular Lymphoma 194


title: Follicular Lymphoma 195


title: Follicular Lymphoma 193


title: Follicular Lymphoma 191


title: Follicular Lymphoma 192


title: Follicular Lymphoma 190


title: Follicular Lymphoma 187


title: Follicular Lymphoma 188


title: Follicular Lymphoma 189


title: Follicular Lymphoma 186


title: Follicular Lymphoma 201


title: Follicular Lymphoma 183


title: Follicular Lymphoma 185


title: Follicular Lymphoma 180


title: Follicular Lymphoma 181


title: Follicular Lymphoma 182


title: Follicular Lymphoma 179


title: Follicular Lymphoma 177


title: Follicular Lymphoma 176


title: Follicular Lymphoma 175


title: Follicular Lymphoma 174


title: Follicular Lymphoma 172


title: Follicular Lymphoma 171


title: Follicular Lymphoma 170


title: Follicular Lymphoma 168


title: Follicular Lymphoma 169


title: Follicular Lymphoma 167


title: Follicular Lymphoma 164


title: Follicular Lymphoma 184


title: Follicular Lymphoma 162


title: Follicular Lymphoma 163


title: Follicular Lymphoma 165


title: Follicular Lymphoma 160


title: Follicular Lymphoma 161


title: Follicular Lymphoma 156


title: Follicular Lymphoma 157


title: Follicular Lymphoma 154


title: Follicular Lymphoma 158


title: Follicular Lymphoma 155


title: Follicular Lymphoma 153


title: Follicular Lymphoma 152


title: Follicular Lymphoma 178


title: Follicular Lymphoma 151


title: Follicular Lymphoma 149


title: Follicular Lymphoma 148


title: Follicular Lymphoma 173


title: Follicular Lymphoma 146


title: Follicular Lymphoma 145


title: Follicular Lymphoma 166


title: Follicular Lymphoma 142


title: Follicular Lymphoma 159


title: Follicular Lymphoma 144


title: Follicular Lymphoma 136


title: Follicular Lymphoma 139


title: Follicular Lymphoma 138


title: Follicular Lymphoma 137


title: Follicular Lymphoma 132


title: Follicular Lymphoma 133


title: Follicular Lymphoma 128


title: Follicular Lymphoma 129


title: Follicular Lymphoma 134


title: Follicular Lymphoma 143


title: Follicular Lymphoma 127


title: Follicular Lymphoma 131


title: Follicular Lymphoma 126


title: Follicular Lymphoma 130


title: Follicular Lymphoma 147


title: Follicular Lymphoma 123


title: Follicular Lymphoma 135


title: Follicular Lymphoma 122


title: Follicular Lymphoma 150


title: Follicular Lymphoma 125


title: Follicular Lymphoma 120


title: Follicular Lymphoma 119


title: Follicular Lymphoma 141


title: Follicular Lymphoma 118


title: Follicular Lymphoma 140


title: Follicular Lymphoma 116


title: Follicular Lymphoma 117


title: Follicular Lymphoma 115


title: Follicular Lymphoma 114


title: Follicular Lymphoma 112


title: Follicular Lymphoma 110


title: Follicular Lymphoma 108


title: Follicular Lymphoma 109


title: Follicular Lymphoma 106


title: Follicular Lymphoma 105


title: Follicular Lymphoma 104


title: Follicular Lymphoma 124


title: Follicular Lymphoma 101


title: Follicular Lymphoma 100


title: Follicular Lymphoma 99


title: Follicular Lymphoma 103


title: Follicular Lymphoma 121


title: Follicular Lymphoma 96


title: Follicular Lymphoma 111


title: Follicular Lymphoma 97


title: Follicular Lymphoma 98


title: Follicular Lymphoma 94


title: Follicular Lymphoma 95


title: Follicular Lymphoma 91


title: Follicular Lymphoma 93


title: Follicular Lymphoma 89


title: Follicular Lymphoma 113


title: Follicular Lymphoma 90


title: Follicular Lymphoma 88


title: Follicular Lymphoma 87


title: Follicular Lymphoma 107


title: Follicular Lymphoma 86


title: Follicular Lymphoma 82


title: Follicular Lymphoma 83


title: Follicular Lymphoma 80


title: Follicular Lymphoma 102


title: Follicular Lymphoma 79


title: Follicular Lymphoma 81


title: Follicular Lymphoma 78


title: Follicular Lymphoma 77


title: Follicular Lymphoma 75


title: Follicular Lymphoma 74


title: Follicular Lymphoma 72


title: Follicular Lymphoma 73


title: Follicular Lymphoma 71


title: Follicular Lymphoma 70


title: Follicular Lymphoma 69


title: Follicular Lymphoma 66


title: Follicular Lymphoma 68


title: Follicular Lymphoma 67


title: Follicular Lymphoma 65


title: Follicular Lymphoma 63


title: Follicular Lymphoma 60


title: Follicular Lymphoma 64


title: Follicular Lymphoma 92


title: Follicular Lymphoma 59


title: Follicular Lymphoma 58


title: Follicular Lymphoma 84


title: Follicular Lymphoma 56


title: Follicular Lymphoma 61


title: Follicular Lymphoma 85


title: Follicular Lymphoma 76


title: Follicular Lymphoma 52


title: Follicular Lymphoma 54


title: Follicular Lymphoma 50


title: Follicular Lymphoma 49


title: Follicular Lymphoma 46


title: Follicular Lymphoma 45


title: Follicular Lymphoma 47


title: Follicular Lymphoma 48


title: Follicular Lymphoma 43


title: Follicular Lymphoma 44


title: Diffusse large B-cell Lymphoma 31


title: Follicular Lymphoma 40


title: Follicular Lymphoma 62


title: Follicular Lymphoma 41


title: Follicular Lymphoma 42


title: Follicular Lymphoma 39


title: Follicular Lymphoma 37


title: Follicular Lymphoma 36


title: Follicular Lymphoma 35


title: Follicular Lymphoma 38


title: Follicular Lymphoma 34


title: Follicular Lymphoma 57


title: Follicular Lymphoma 32


title: Follicular Lymphoma 31


title: Follicular Lymphoma 30


title: Follicular Lymphoma 53


title: Follicular Lymphoma 29


title: Follicular Lymphoma 51


title: Follicular Lymphoma 27


title: Follicular Lymphoma 28


title: Follicular Lymphoma 33


title: Follicular Lymphoma 26


title: Follicular Lymphoma 24


title: Follicular Lymphoma 25


title: Follicular Lymphoma 22


title: Follicular Lymphoma 23


title: Follicular Lymphoma 21


title: Follicular Lymphoma 20


title: Follicular Lymphoma 19


title: Follicular Lymphoma 18


title: Follicular Lymphoma 16


title: Follicular Lymphoma 17


title: Follicular Lymphoma 14


title: Follicular Lymphoma 11


title: Follicular Lymphoma 12


title: Follicular Lymphoma 15


title: Follicular Lymphoma 13


title: Follicular Lymphoma 7


title: Follicular Lymphoma 4


title: Follicular Lymphoma 3


title: Follicular Lymphoma 9


title: Follicular Lymphoma 2


title: Follicular Lymphoma 1


title: Control 730


title: Follicular Lymphoma 5


title: Control 729


title: Control 726


title: Control 728


title: Control 724


title: Control 727


title: Control 725


title: Control 723


title: Control 721


title: Control 720


title: Control 719


title: Control 718


title: Follicular Lymphoma 10


title: Control 716


title: Control 715


title: Control 714


title: Follicular Lymphoma 8


title: Follicular Lymphoma 6


title: Control 713


title: Control 711


title: Control 710


title: Control 709


title: Control 717


title: Control 712


title: Control 707


title: Control 706


title: Control 708


title: Control 705


title: Control 703


title: Control 700


title: Control 699


title: Control 704


title: Control 698


title: Control 702


title: Control 701


title: Control 697


title: Control 722


title: Control 694


title: Control 695


title: Control 696


title: Control 693


title: Control 688


title: Control 689


title: Control 692


title: Control 691


title: Control 680


title: Control 683


title: Control 682


title: Control 686


title: Control 690


title: Control 679


title: Control 676


title: Control 687


title: Control 678


title: Control 677


title: Control 685


title: Control 668


title: Control 684


title: Control 674


title: Control 672


title: Control 667


title: Control 671


title: Control 669


title: Control 673


title: Control 666


title: Control 665


title: Control 670


title: Control 681


title: Control 675


title: Control 663


title: Control 661


title: Control 664


title: Control 662


title: Control 654


title: Control 651


title: Control 658


title: Control 650


title: Control 657


title: Control 649


title: Control 659


title: Control 656


title: Control 648


title: Control 653


title: Control 647


title: Control 644


title: Control 655


title: Control 646


title: Control 643


title: Control 652


title: Control 639


title: Control 642


title: Control 638


title: Control 641


title: Control 640


title: Control 645


title: Control 637


title: Control 636


title: Control 660


title: Control 635


title: Control 633


title: Control 634


title: Control 632


title: Control 630


title: Control 631


title: Control 625


title: Control 627


title: Control 622


title: Control 621


title: Control 628


title: Control 624


title: Control 617


title: Control 620


title: Control 616


title: Control 618


title: Control 626


title: Control 614


title: Control 613


title: Control 611


title: Control 619


title: Control 610


title: Control 612


title: Control 615


title: Control 609


title: Control 607


title: Control 605


title: Control 608


title: Control 604


title: Control 606


title: Control 603


title: Control 600


title: Control 601


title: Control 596


title: Control 595


title: Control 598


title: Control 629


title: Control 594


title: Control 592


title: Control 599


title: Control 588


title: Control 590


title: Control 586


title: Control 593


title: Control 623


title: Control 585


title: Follicular Lymphoma 55


title: Control 583


title: Control 582


title: Control 602


title: Control 597


title: Control 581


title: Control 578


title: Control 579


title: Control 580


title: Control 577


title: Control 576


title: Control 575


title: Control 591


title: Control 574


title: Control 589


title: Control 573


title: Control 570


title: Control 572


title: Control 568


title: Control 565


title: Control 563


title: Control 561


title: Control 587


title: Control 564


title: Control 562


title: Control 584


title: Control 566


title: Control 560


title: Control 558


title: Control 557


title: Control 555


title: Control 556


title: Control 554


title: Control 553


title: Control 552


title: Control 551


title: Control 571


title: Control 549


title: Control 550


title: Control 548


title: Control 567


title: Control 547


title: Control 544


title: Control 569


title: Control 542


title: Control 541


title: Control 546


title: Control 537


title: Control 536


title: Control 559


title: Control 535


title: Control 538


title: Control 534


title: Control 532


title: Control 533


title: Control 531


title: Control 530


title: Control 529


title: Control 526


title: Control 528


title: Control 525


title: Control 527


title: Control 545


title: Control 524


title: Control 543


title: Control 519


title: Control 517


title: Control 521


title: Control 520


title: Control 540


title: Control 523


title: Control 516


title: Control 539


title: Control 513


title: Control 518


title: Control 515


title: Control 512


title: Control 514


title: Control 511


title: Control 509


title: Control 508


title: Control 510


title: Control 507


title: Control 506


title: Control 504


title: Control 503


title: Control 502


title: Control 501


title: Control 499


title: Control 522


title: Control 498


title: Control 497


title: Control 496


title: Control 495


title: Control 491


title: Control 493


title: Control 489


title: Control 492


title: Control 488


title: Control 494


title: Control 486


title: Control 505


title: Control 485


title: Control 482


title: Control 483


title: Control 481


title: Control 484


title: Control 478


title: Control 479


title: Control 477


title: Control 476


title: Control 472


title: Control 473


title: Control 471


title: Control 470


title: Control 469


title: Control 468


title: Control 490


title: Control 487


title: Control 466


title: Control 463


title: Control 464


title: Control 461


title: Control 465


title: Control 500


title: Control 460


title: Control 462


title: Control 457


title: Control 455


title: Control 454


title: Control 452


title: Control 480


title: Control 453


title: Control 475


title: Control 456


title: Control 459


title: Control 450


title: Control 474


title: Control 451


title: Control 448


title: Control 449


title: Control 447


title: Control 445


title: Control 467


title: Control 446


title: Control 444


title: Control 443


title: Control 439


title: Control 441


title: Control 458


title: Control 442


title: Control 440


title: Control 437


title: Control 438


title: Control 436


title: Control 434


title: Control 432


title: Control 433


title: Control 426


title: Control 429


title: Control 430


title: Control 431


title: Control 427


title: Control 428


title: Control 422


title: Control 423


title: Control 424


title: Control 420


title: Control 425


title: Control 419


title: Control 418


title: Control 417


title: Control 435


title: Control 416


title: Control 415


title: Control 414


title: Control 410


title: Control 412


title: Control 409


title: Control 411


title: Control 405


title: Control 404


title: Control 407


title: Control 402


title: Control 403


title: Control 408


title: Control 406


title: Control 421


title: Control 396


title: Control 398


title: Control 397


title: Control 399


title: Control 400


title: Control 401


title: Control 395


title: Control 393


title: Control 394


title: Control 392


title: Control 391


title: Control 390


title: Control 413


title: Control 389


title: Control 388


title: Control 386


title: Control 384


title: Control 387


title: Control 385


title: Control 383


title: Control 380


title: Control 382


title: Control 378


title: Control 381


title: Control 375


title: Control 373


title: Control 379


title: Control 371


title: Control 367


title: Control 377


title: Control 368


title: Control 376


title: Control 366


title: Control 372


title: Control 364


title: Control 362


title: Control 363


title: Control 360


title: Control 358


title: Control 359


title: Control 361


title: Control 357


title: Control 354


title: Control 355


title: Control 356


title: Control 353


title: Control 374


title: Control 352


title: Control 351


title: Control 348


title: Control 349


title: Control 370


title: Control 350


title: Control 369


title: Control 346


title: Control 347


title: Control 341


title: Control 340


title: Control 342


title: Control 344


title: Control 365


title: Control 339


title: Control 345


title: Control 343


title: Control 335


title: Control 336


title: Control 333


title: Control 334


title: Control 332


title: Control 337


title: Control 331


title: Control 330


title: Control 328


title: Control 327


title: Control 329


title: Control 325


title: Control 326


title: Control 324


title: Control 321


title: Control 323


title: Control 322


title: Control 318


title: Control 320


title: Control 316


title: Control 319


title: Control 314


title: Control 317


title: Control 313


title: Control 338


title: Control 315


title: Control 312


title: Control 309


title: Control 310


title: Control 308


title: Control 307


title: Control 306


title: Control 305


title: Control 303


title: Control 304


title: Control 302


title: Control 301


title: Control 299


title: Control 297


title: Control 298


title: Control 300


title: Control 296


title: Control 295


title: Control 294


title: Control 293


title: Control 311


title: Control 292


title: Control 290


title: Control 287


title: Control 289


title: Control 288


title: Control 286


title: Control 291


title: Control 285


title: Control 283


title: Control 284


title: Control 282


title: Control 278


title: Control 280


title: Control 279


title: Control 281


title: Control 277


title: Control 276


title: Control 274


title: Control 275


title: Control 273


title: Control 272


title: Control 271


title: Control 270


title: Control 269


title: Control 268


title: Control 267


title: Control 266


title: Control 262


title: Control 265


title: Control 263


title: Control 261


title: Control 258


title: Control 254


title: Control 257


title: Control 259


title: Control 252


title: Control 255


title: Control 253


title: Control 250


title: Control 251


title: Control 249


title: Control 247


title: Control 246


title: Control 244


title: Control 243


title: Control 242


title: Control 241


title: Control 239


title: Control 240


title: Control 238


title: Control 237


title: Control 264


title: Control 235


title: Control 234


title: Control 256


title: Control 233


title: Control 231


title: Control 260


title: Control 230


title: Control 229


title: Control 245


title: Control 226


title: Control 225


title: Control 227


title: Control 248


title: Control 223


title: Control 224


title: Control 236


title: Control 219


title: Control 218


title: Control 232


title: Control 217


title: Control 216


title: Control 228


title: Control 215


title: Control 214


title: Control 213


title: Control 212


title: Control 222


title: Control 211


title: Control 221


title: N_2847_0h

city: Lindau

first: Stefan

middle: Michael

last: Bauersachs

state: Zurich

address: Eschikon 27 EHB 23.1

department: Department for Farm Animals

country: Switzerland

institute: University of Zurich

description: control dog before patch test

hyb_protocol: Microarray analysis was performed using custom Agilent 8x60k Dog Gene Expression microarrays (AMADID 031538). Labeled cRNA was hybridized to the microarrays according the manufacturer’s instructions.

scan_protocol: Hybridized and washed slides were scanned at 3 µm resolution, 20 bit option, single pass with an Agilent DNA Microarray Scanner (G2505C, Agilent Technologies).

data_processing: Image processing was performed with Feature Extraction Software 10.7.3.1 (Agilent Technologies) using default parameters (protocol GE1_107_Sep09) to obtain background subtracted and spatially detrended 'Processed Signal' intensities.

organism: Canis lupus familiaris

label_protocol: Cy3-labeled cRNA was produced using the Quick Amp Labeling Kit, one-color (Agilent Technologies) according the manufacturer’s instructions.

extract_protocol: Total RNA was isolated from the 60 skin biopsy samples using Trizol® Reagent (Invitrogen GmbH, Karlsruhe, Germany) according to the manufacturer’s instructions. Quantity and purity of RNA were measured with a NanoDrop 1000 (PEQLAB Biotechnologie GMBH, Erlangen, Germany). Quality of total RNA was assessed by electrophoresis using an Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).

treatment_protocol: Skin biopsy samples were collected from six non-allergic control Beagle dogs (2 males and 4 females) and six Beagle dogs sensitized Dermatophagoides farinae (4 males and 2 females). Sensitization was documented by positive reactions to intradermal testing (IDT) with D. farinae antigen and an elevated serum concentration of D. farinae-specific IgE. The age of the dogs ranged from 2-3 years (mean of 2.3 years). Environmental and feeding conditions were the same for all dogs. A 10 x 10 cm area on the lateral chest of each dog was shaved with a clipper blade (Favorita II GT 104, Aesculap AG, Germany).  Four days later a patch test (PT) was conducted with 75 mg of HDM paste (powder of milled dust mite, 99% pure Dermatophagoides farinae, Greer Laboratories, North Carolina, mixed with saline to a pasty consistency) and 50μl of physiologic saline as a negative control. The patch test sites were bandaged carefully to prevent trauma or movement of the patches. In addition, each dog wore a mesh body suit. The allergen patch test was carefully relocated in the exact same position and bandages were replaced at the 6 hour intervention. In total, five 8 mm punch biopsies were taken from each dog using local anesthesia, each site with 0.5 ml of 2% lidocaine (Vetoquinol AG, Ittingen, Switzerland). One specimen was obtained before (0 h) and two biopsies each at 6 and 24 hours (6 h, 24 h) at the patch test site of both allergen (A) and saline (S) applications. After clipping and at each time point (0 h, 6 h, 24 h) before collecting the biopsies, skin was evaluated for signs of inflammation. In order to investigate the cellular response and gene expression in the skin, biopsies were cut into three pieces with two parallel cuts. The middle part of each specimen was placed in 10% neutrally buffered formalin. The other two pieces were placed into RNAlater™ (Qiagen GmbH, Hilden, Germany) and after four days of storage at 4°C, these specimens were stored at -20°C until further processing.

tag: group

value: not sensitized dogs

tag: animal #

tag: time

tag: treatment

value: skin


title: Control 220


title: N_2847_6h_A

description: control dog 6h after patch test with allergen

value: allergen


title: N_2845_24h_A

description: control dog 24h after patch test with allergen


title: Control 210


title: N_2847_24h_A


title: N_2802_24h_S

description: control dog 24h after patch test with saline as control for systemic effects

value: saline


title: N_2802_6h_A


title: N_2802_24h_A


title: N_2847_6h_S

description: control dog 6h after patch test with saline as control for systemic effects


title: Control 209


title: N_2847_24h_S


title: N_2802_6h_S


title: N_2845_24h_S


title: N_2845_6h_S


title: N_2845_6h_A


title: Control 208


title: Control 207


title: Control 206


title: Control 205


title: Control 204


title: Control 203


title: N_2845_0h

description: control dog before patch test


title: Control 202


title: Control 201


title: Control 198


title: Control 200


title: Control 197


title: Control 199


title: Control 196


title: N_2800_24h_A


title: N_2800_6h_S


title: N_2802_0h

description: control dog before patch test


title: N_2800_6h_A


title: N_2716_24h_S


title: Control 194


title: Control 193


title: N_2800_24h_S


title: N_2716_24h_A


title: N_2800_0h

description: control dog before patch test


title: Control 191


title: N_2704_24h_A


title: N_2704_6h_S


title: N_2716_6h_S


title: Control 195


title: N_2716_0h

description: control dog before patch test


title: Control 190


title: Control 189


title: N_2704_24h_S


title: Control 188


title: A_2855_6h_S

description: allergic dog 6h after patch test with saline as control for systemic effects

value: sensitized dogs


title: Control 186


title: Control 187


title: N_2716_6h_A


title: N_2704_0h

description: control dog before patch test


title: N_2704_6h_A


title: A_2855_24h_S

description: allergic dog 24h after patch test with saline as control for systemic effects


title: A_2855_6h_A

description: allergic dog 6h after patch test with allergen


title: Control 185


title: Control 192


title: Control 184


title: Control 183


title: Control 181


title: Control 180


title: Control 179


title: A_2853_24h_S


title: A_2853_6h_S


title: Control 178


title: A_2855_0h

description: allergic dog before patch test


title: A_2841_24h_A

description: allergic dog 24h after patch test with allergen


title: Control 177


title: Control 175


title: A_2853_24h_A


title: Control 174


title: A_2853_0h

description: allergic dog before patch test


title: A_2853_6h_A


title: Control 173


title: Control 182


title: A_2855_24h_A


title: A_2841_24h_S


title: A_2841_6h_S


title: A_2841_6h_A


title: A_2841_0h

description: allergic dog before patch test


title: A_2840_24h_S


title: Control 172


title: Control 171


title: Control 176


title: Control 170


title: Control 169


title: Control 168


title: Control 167


title: A_2840_24h_A


title: Control 166


title: Control 164


title: Control 165


title: Control 163


title: A_2840_0h

description: allergic dog before patch test


title: Control 162


title: A_2839_24h_A


title: A_2839_24h_S


title: A_2840_6h_S


title: A_2840_6h_A


title: A_2839_6h_S


title: A_2839_0h

description: allergic dog before patch test


title: A_2839_6h_A


title: A_2838_6h_S


title: A_2838_24h_A


title: A_2838_0h

description: allergic dog before patch test


title: Control 161


title: Control 159


title: Control 158


title: Control 160


title: rat hippocampus, high vitamin D, 18 months old, marked, subject 25

city: Lexington

first: Eric

middle: M

last: Blalock

state: KY

address: 800 Rose St.

department: Molecular and Biomedical Pharmacology

institute: University of Kentucky

hyb_protocol: Standard Affymetrix- 20μg biotin-labeled cRNA was applied to a Affymetrix Rat Gene 1.0 ST array for hybridization (one chip per animal).

scan_protocol: standard Affymetrix protocol

data_processing: Quality control and signal intensity calculations were performed in Partek (v. 6.6), with additional residual image analysis done in RMAexpress. The gcRMA probe level summary algorithm was used to estimate signal intensity at the gene (rather than exon) level using Partek's default settings.

organism: Rattus norvegicus

source_name: high vitamin D_18 months old_marked

label_protocol: For each sample, 20 μg of biotin-labeled cRNA was generated from 5μg of total RNA according to manufacturer’s instructions (Standard Affymetrix).

extract_protocol: RNA was extracted from each hippocampal tissue block, as described previously (Blalock et al., 2003; Kadish et al., 2009; Rowe et al., 2007) using TRIzol (Invitrogen) followed by ethanol precipitation, and was reconstituted in RNase-free water (Standard Affymetrix)

value: Fisher 344

tag: gender

value: male

tag: diet group

value: high vitamin D

value: hippocampus


title: rat hippocampus, high vitamin D, 18 months old, unmarked, subject 19

source_name: high vitamin D_18 months old_unmarked

tag: strain


title: A_2838_24h_S


title: rat hippocampus, high vitamin D, 18 months old, marked, subject 24


title: Control 157


title: A_2838_6h_A


title: rat hippocampus, high vitamin D, 18 months old, marked, subject 22


title: rat hippocampus, high vitamin D, 18 months old, unmarked, subject 23


title: rat hippocampus, control, 18 months old, unmarked, subject 17

source_name: control_18 months old_unmarked


title: rat hippocampus, control, 18 months old, marked, subject 16

source_name: control_18 months old_marked


title: rat hippocampus, high vitamin D, 18 months old, unmarked, subject 21


title: rat hippocampus, high vitamin D, 18 months old, marked, subject 20


title: rat hippocampus, control, 18 months old, unmarekd, subject 15

source_name: control_18 months old_unmarkd


title: rat hippocampus, control, 18 months old, unmarked, subject 13


title: rat hippocampus, high vitamin D, 18 months old, marked, subject 18


title: Sorted Thy+ cells from Rep-MEFs expressing OKSM for 3 days

city: Boston

first: Ori

last: Bar-Nur

state: MA

address: 185 Cambridge st.

department: Center of Regenerative medicine

institute: Harvard University

description: Sorted refractory Thy1+ cells

hyb_protocol: Hybridization was done by the Partners Center for Personalized Genetic Medicine.

scan_protocol: Scanning was done by the Partners Center for Personalized Genetic Medicine.

data_processing: Data was processed using Expression Console software, the processing algorithm was RMA

source_name: Sorted refractory Thy1+ cells

label_protocol: Labeling was done by the Partners Center for Personalized Genetic Medicine.

growth_protocol: Cells were grown in ESC media or MEFs mefia depencing on the cell type as described in the materials section

extract_protocol: RNA (Dnase treated) was islolated and extracted using the Rneasy Mini Kit (Qiagen).

treatment_protocol: Cells were treated with ascorbic acid and GSK3i, control cells did not.

tag: cell type

value: Sorted Thy+ cells from Rep-MEFs

tag: genotype/variation

value: expressing OKSM

value: 3 days


title: rat hippocampus, control, 18 months old, marked, subject 12


title: rat hippocampus, control, 18 months old, marked, subject 10


title: rat hippocampus, high vitamin D, 18 months old, unmarked, subject 26


title: rat hippocampus, control, 18 months old, unmarked, subject 11


title: rat hippocampus, control, 18 months old, unmarked, subject 9


title: rat hippocampus, control, 18 months old, marked, subject 14


title: Rep-MEFs express OKSM+ascorbic acid and GSK3i for 10 days

description: Rep-MEFs+OKSM+AGi 10days

source_name: Rep-MEFs+OKSM+AGi 10days

value: Bulk Rep-MEF population

tag: treatment protocol

value: AGi

value: 10 days


title: rat hippocampus, low vitamin D, 18 months old, unmarked, subject 8

source_name: low vitamin D_18 months old_unmarked

value: low vitamin D

tag: tissue


title: Rep-MEFs express OKSM for 12 days

description: Rep-MEFs+OKSM 12days

source_name: Rep-MEFs+OKSM 12days

value: 12 days


title: Rep-MEFs express OKSM+ascorbic acid and GSK3i for 12 days

description: Rep-MEFs+OKSM+AGi 12days

source_name: Rep-MEFs+OKSM+AGi 12 days


title: rat hippocampus, low vitamin D, 18 months old, marked, subject 7

source_name: low vitamin D_18 months old_marked


title: LCS-425A

city: Bethesda

first: Xin

middle: Wei

last: Wang

state: MD

address: 37 Convent Drive

department: Laboratory of Human Carcinogenesis

institute: National Cancer Institute

description: No additional information.

hyb_protocol: Illumina Hybridization Protocol Hybridization was performed following the manufacturer's protocol for Illumina's Infinium Human Methylation27 BeadChip microarrays.

scan_protocol: Illumina Scanning Protocol Illumina's Infinium Human Methylation27 BeadChip microarrays were scanned using a HiScan (Illumina). Images were analyzed using BeadStudio software (Illumina).

data_processing:
Data Processing Protocol
Calculation Method: Raw data from the Infinium Human Methylation27 BeadChip microarrays were extracted using BeadStudio software (Illumina). Thereafter, the SSN method in the R lumi package was used to normalize the data. Further analysis was carried out using the lumi package in R. IlluminaHumanMethylation27k.db_1.4.7 package (http://www.bioconductor.org) was used for annotation. Only probes which did not have any NAs were included which resulted in 23,972 probes.

label_protocol:
Zymo EZ DNA Methylation
Used 1 ug of high quality DNA and completed the bisulfite conversion according to the manufacturer's protocol (Zymo Research Corporation, Irvine, CA).

extract_protocol:
Phenol/Chloroform Extraction Protocol
Other: DNA was extracted using Phenol/Chloroform/Isoamyl Alcohol (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.

value: female

value: Liver Tumor Tissue

tag: disease state

value: Hepatocellular carcinoma (HCC)

tag: hbv viral status

value: AVR-CC

tag: alt

value: low

tag: main tumor size

value: large

tag: multinodular

value: No

tag: cirrhosis

value: Yes

tag: tnm staging

value: I

tag: bclc staging

value: A

tag: clip staging

tag: afp

tag: survival status

value: Alive

tag: survival months

tag: recurr status

value: False

tag: recurr months


title: LCS-424A

description: No additional information.

tag: gender

value: male

tag: age

tag: hbv viral status:

tag: tnm staging:

tag: bclc staging:

tag: clip staging:

value: high


title: rat hippocampus, low vitamin D, 18 months old, marked, subject 5

tag: strain

value: Fisher 344

tag: diet group

tag: tissue

value: hippocampus


title: rat hippocampus, low vitamin D, 18 months old, unmarked, subject 4

value: low vitamin D


title: Rep-MEFs express OKSM for 10 days

description: Rep-MEFs+OKSM 10days

source_name: Rep-MEFs+OKSM 10days

tag: cell type

value: Bulk Rep-MEF population

tag: genotype/variation

value: expressing OKSM

tag: time

value: 10 days


title: rat hippocampus, low vitamin D, 18 months old, marked, subject 3


title: LCS-421A

description: No additional information.

value: Liver Tumor Tissue

tag: disease state

value: Hepatocellular carcinoma (HCC)

tag: hbv viral status

value: N

tag: alt

tag: main tumor size

tag: multinodular

tag: cirrhosis

tag: tnm staging

tag: bclc staging

tag: clip staging

tag: afp


title: rat hippocampus, low vitamin D, 18 months old, unmarked, subject 6

tag: gender


title: rat hippocampus, low vitamin D, 18 months old, unmarked, subject 2

tag: strain


title: Rep-MEFs express OKSM+ascorbic acid and GSK3i for 8 days

description: Rep-MEFs+OKSM+AGi 8days

source_name: Rep-MEFs+OKSM+AGi 8days

tag: treatment protocol

value: AGi

value: 8 days


title: Rep-MEFs express OKSM for 8 days


title: LCS-420A

description: No additional information.

tag: age

tag: tissue

value: CC

value: low

value: large

value: Yes

value: No

value: IIIA

value: B

tag: survival status

tag: survival months

tag: recurr status

tag: recurr months


title: LCS-413A

description: No additional information.

value: male

tag: disease state

tag: hbv viral status

tag: alt

value: small

value: I

value: A

value: Alive

value: True


title: rat hippocampus, low vitamin D, 18 months old, marked, subject 1

value: Fisher 344

tag: diet group

value: low vitamin D

value: hippocampus


title: LCS-411A

description: No additional information.

value: Liver Tumor Tissue

value: Hepatocellular carcinoma (HCC)

value: high

tag: main tumor size

tag: multinodular

tag: cirrhosis

tag: tnm staging

value: II

value: Dead


title: LCS-410A

description: No additional information.

tag: gender

value: CC

value: Yes

tag: bclc staging

tag: clip staging

tag: afp

value: False


title: Rep-MEFs express OKSM+ascorbic acid and GSK3i for 6 days

description: Rep-MEFs+OKSM+AGi 6days

source_name: Rep-MEFs+OKSM+AGi 6days

tag: strain

tag: cell type

value: Bulk Rep-MEF population

tag: genotype/variation

value: expressing OKSM

tag: treatment protocol

value: AGi

tag: time

value: 6 days